Preclinical Testing of Erlotinib in a Transgenic Alveolar Rhabdomyosarcoma Mouse Model
Figure 2
Tumor growth and weight loss in rhabdomyosarcoma-bearing mice treated with Erlotinib. (a) Tumor growth over time in mice which had tumors smaller than 0.4 cc at diagnosis. The 50th percentile represents control (untreated) tumor-bearing mice. (b) Tumor growth over time in mice which had tumors larger than 0.4 cc at diagnosis. The 50th percentile represents control (untreated) tumor-bearing mice. (c) Animal body weights over the duration of therapy.
